TNFSF13B Antibodies

Tumor necrosis factor ligand superfamily member 13B (TNFSF13B)

Cytokine that binds to TNFRSF13B/TACI and TNFRSF17/BCMA.

TNFSF13/APRIL binds to the exact same 2 receptors.

Collectively, they form a two ligands -2 receptors pathway involved in the stimulation of B- and T-cell function and the regulation of humoral immunity. A third B-cell specific BAFF-receptor (BAFFR/BR3) promotes the survival of older B-cells and the B-cell response.

Gene Information

Human
Gene Name:	TNFSF13B
Uniprot:	Q9Y275
Entrez:	10673

Family

Belongs to:
tumor necrosis factor family

Alternative Names

ApoL related ligand TALL-1; B lymphocyte stimulator; BAFF; BAFFB-cell activating factor; B-cell-activating factor; BLyS; BLYSB-lymphocyte stimulator; CD257 antigen; CD257; Dendritic cell-derived TNF-like molecule; DTL; TALL1; TALL-1delta BAFF; TALL1Delta4 BAFF; THANK; TNF- and APOL-related leukocyte expressed ligand 1; TNF and ApoL-related leukocyte expressed ligand 1; TNF homolog that activates apoptosis; TNFSF13B; TNFSF20; tumor necrosis factor (ligand) superfamily, member 13b; tumor necrosis factor (ligand) superfamily, member 20; tumor necrosis factor ligand superfamily member 13B; tumor n

Molecular Weight

Mass (kDA):
31.223 kDA

Genomic Context

Human
Location:	13q33.3
Sequence:	13; NC_000013.11 (108268240..108308484)

Tissue Specificity

Abundantly expressed in peripheral blood Leukocytes and is specifically expressed in monocytes and macrophages. Also found in the spleen, lymph node, bone marrow, T- cells and dendritic cells. A lower expression seen in placenta, heart, lung, fetal liver, thymus, and pancreas. Isoform 2 is expressed in many myeloid cell lines.

Subcellular Localizations

Cell membrane; Single-pass type II membrane protein.; [Tumor necrosis factor ligand superfamily member 13b, soluble form]: Secreted.

Diseases

• Autoimmune Reaction
• Autoimmune Diseases
• Lupus Erythematosus, Systemic
• Autoimmunity
• Arthritis
• Rheumatoid Arthritis
• Malignant Neoplasms
• Sjogren's Syndrome
• Neoplasms
• Lymphoma
• Inflammation
• B-cell Lymphomas
• Malignant Paraganglionic Neoplasm

• Multiple Myeloma
• Sclerosis
• Immunologic Deficiency Syndromes
• Leukemia
• Multiple Sclerosis
• Salivary Gland Diseases
• Chronic Lymphocytic Leukemia

Interacting Proteins

• CSE1L
• KPNB1
• TNFRSF13B

Pathways

• Pathogenesis
• Cell Activation
• Cell Maturation
• Secretion
• B Cell Activation
• Cell Proliferation
• Cell Development
• B Cell Proliferation
• Immune Response
• B Cell Homeostasis
• Cell Growth
• Immunoglobulin Production
• T Cell Activation

• Cell Death
• Cell Differentiation
• Cell Cycle
• Lymphocyte Proliferation
• B Cell Differentiation
• Germinal Center Formation
• Localization

PTMs

• Phosphorylation
• Cleavage
• Citrullination

• Glycosylation
• Dephosphorylation
• Methylation

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/TNFSF13B

Best Uses Of The TNFSF13B Marker For B-Lineage Lymphoma

You've come to the right place to find an TNFSF13B marker. We'll talk about the Boster Bio Anti–CD40/Cd40 Protein Picoband(tm), and the TNFSF13B marker for B-lineage Lymphoblastic leukemia. After reading the article, you'll understand why Boster's TNFSF13B marker is one of the most effective products that are available.

Boster Bio Anti-CD40/Cd40 Antibody Picoband(tm)

Boster Bio Anti CD40/Cr–Cd40 Antibody Picoband(TM) is a highly-specific, high-resolution monoclonal antibody against the CD40/Cr–Cd40 receptor. It is part of the TNF-receptor superfamily and is expressed on many types of cells including monocytes, thymic epithelium and dendritic cells. It is a member the TNF gene family, and plays a significant function in mediating immune and inflammation-related responses. It is controlled by the AT-hook transcription factor AKNA and is found on all human cells including T cells. This receptor is required to activate B cells. It has also been proven to inhibit certain kinds of B cells.

This Boster Bio Anti-CD40/CDR Fc Polyclonal Antibody reacts with Mouse. It can be stored at -20°C or frozen for up to 6 months. It is made up of 5 mg BSA and 0.05mg Thimerosal per vial. The antibody is also available with blocking peptides that are specific to a particular length of immunogen.

Boster Bio Anti-BAFF TNFSF13B Antibody

The anti-BAFF anti-Boster antibody that was purified was biotinylated by EZ-link NHS Biotin by Thermo Fisher Scientific. Purification of polyclonal antibodies was approved by the Ethics Committee of Instituto Nacional de Investigacion y Tecnologia Alimentaria (INA).

This antibody reacts with BAFF in a mouse model in a dose-dependent manner. It is compatible with mouse, human and rat specimens. The maximum concentration is 5 ng/mL. It reacts with the antigen on a range of cellular types, including Human, Mouse, and Zebrafish. This antibody is not compatible with antibodies that are similar to other ligands such as IgM.

This polyclonal antibody was created in mice by BAF recombinant from trout. It blocks BAFF binding to B cells. This antibody recognized the BAFF protein on the membranes of mice's lymphocytes spleens, reducing BAFF binding to undetectable levels. Thus, the antibody is extremely specific and can be used for research purposes. It lets scientists study BAFF binding using a mouse model in an extremely precise manner.

TNFSF13B antibodies are effective in a variety conditions. Anti-BAFF TNFSF13B can be beneficial for those suffering from inflammatory diseases such as RA and SLE. It blocks growth tumor cells. These antibodies function by interfering with the receptor of the BAFF ligand (BCF-Ig).

Boster's TNFSF13B marker

A recent study has revealed elevated levels of TNFSF13B and TNFSF14 levels in the secretions of infants suffering from severe RSV and other infections. These markers were discovered in children suffering from HAdV associated pneumonia. However they did not signify an acute episode. These markers can be used to determine the severity and progression of an illness in a child.

Recent research has shown that TNFSF14 enhances lung-resident circulating memories CD8+ T cells in patients suffering from HAdV-related pneumonia. Additionally, TNFSF14 was significantly elevated in the serum of COVID-19 sufferers with cytokine release syndrome. Additionally, this molecule has been involved in the pathophysiology of pulmonary diseases such as pulmonary and fibrosis. Patients suffering from pulmonary fibrosis showed high levels of TNF13B in their bronchoalveolar fluid.

This study was conducted to determine the function of the TNFSF/TNFRSF system in the plasma of children suffering from HAdV pneumonia. The authors concluded that TNFSF13B, and TNFSF14 could be markers of inflammation in the system for severe HAdV infections. This study was conducted in accordance to the Declaration of Helsinki and Ethics Committee of Guangzhou Women and Children's Medical Center. Patients gave written informed consent.

Boster's TNFSF13B marker to identify B-lineage lymphoblastic Leukemia

The B-lineage allele of TNFSF13B is a unique diagnostic antigen used to determine the presence of B-lineage leukemia. This antibody detects cells of leukemia that express the B-lineage TNFSF13B antigen. This antibody is highly specific, allowing doctors to detect rare tumors early in the treatment process.

The median age of study participants was 66.1 years old and 56.7 percent of them were male. The anti-HBs/HBc positive percentage was 86.8 percent, and the HBV RS percentage was 14. Within the SNPs that were identified, nine were associated with HBV-RS while eight were associated with the disease. HBV-RS is caused by IL4 rs2243248, and IL4 rs2243263.

The use of CAR-based treatments based on chimeric antigen receptors may help patients with this disease. A recent study revealed that these treatments cut down the risk of relapse , and increased the duration of survival for patients. The use of CAR-T cells in the treatment for B-lineage acute Lymphoblastic Leukemia was evaluated by researchers from the National Cancer Institute and the Cleveland Clinic.

The study revealed that 255 genes were overexpressed and 170 genes were downregulated. The majority of the genes that were overexpressed had a twofold increase in expression and 12 gene-regulatory factors 13B (TNFSF13B). These markers were associated to biological pathways that are crucial to the treatment and prevention of B-lineage lymphoblastic Leukemia.

Activation of BAFF-R has been reported as an essential determinant of B-cell survival in the bone marrow. BAFF-R stimulates NF-kB signaling to prevent spontaneous apoptosis in lymphoma B cells. The results of this study are promising for further research in this area.